33 completed, 4 recruiting, 3 withdrawn, 1 active not recruiting. 15 Phase 2, 14 Phase 1, 14 Phase 3, 1 Phase 4.
Follow Akebia Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis Epoetin alga (Epogen)/vadadustat - Anemia Associated With Chronic Kidney Disease | Phase 3 | Not yet recruiting | Geoff Block | 100 | 2026-04-01 | 2026-05-04 |
| SAD and MAD Study of AKB-9090 in Healthy Adult Participants AKB-9090, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Akebia Therapeutics | 44 | 2026-03-16 | 2026-10-06 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-10-01 |
| Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury Vadadustat 900mg, Vadadustat 1200mg, Placebo - Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury | Phase 2 / Phase 3 | Recruiting | Paul Potnuru | 1100 | 2025-10-23 | 2026-08-10 |
| To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Erythropoiesis-Stimulating Agent (ESA), Vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Completed | Akebia Therapeutics | 353 | 2025-07-24 | 2026-09-04 |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Withdrawn | Akebia Therapeutics | 2025-01-01 | 2025-10-01 | |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents Vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Withdrawn | Akebia Therapeutics | 2025-01-01 | 2025-10-01 | |
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Active not recruiting | USRC Kidney Research | 2200 | 2024-11-20 | 2026-03-10 |
| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo - Anemia, Iron Deficiency, Hyperphosphatemia | Phase 3 | Completed | USRC Kidney Research | 289 | 2022-03-30 | 2025-08-29 |
| Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy - Hyperphosphatemia, Anemia, Iron Deficiency | Phase 4 | Completed | USRC Kidney Research | 214 | 2021-06-29 | 2022-11-07 |
| Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects Vadadustat, Mircera® - Anemia Associated With Chronic Kidney Disease (CKD) | Phase 3 | Completed | Akebia Therapeutics | 456 | 2021-06-18 | 2025-01-15 |
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) vadadustat, placebo - Acute Respiratory Distress Syndrome, Coronavirus Infection | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 448 | 2020-08-22 | 2025-03-26 |
| Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat Vadadustat, Sevelamer carbonate, Calcium acetate - Healthy Volunteers | Phase 1 | Completed | Akebia Therapeutics | 54 | 2020-06-15 | 2020-10-08 |
| Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) Vadadustat, Darbepoetin alfa - Anemia | Phase 3 | Completed | Akebia Therapeutics | 319 | 2020-05-27 | 2025-05-22 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Vadadustat, Darbepoetin alfa, Epoetin alfa - Anemia Associated With Chronic Kidney Disease | Phase 1 | Completed | Akebia Therapeutics | 46 | 2019-05-28 | 2020-09-16 |
| Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Vadadustat, Epoetin Alfa, Vadadustat TIW - Anemia, Dialysis-dependent Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 175 | 2019-01-31 | 2022-09-29 |
| Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Vadadustat, Rabeprazole - Drug Interaction Potentiation, Pharmacokinetics | Phase 1 | Completed | Akebia Therapeutics | 20 | 2018-10-03 | 2019-03-22 |
| A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet vadadustat - Healthy | Phase 1 | Completed | Akebia Therapeutics | 54 | 2018-08-03 | 2019-03-22 |
| Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Vadadustat, Furosemide, Adefovir - Drug Interaction Potentiation | Phase 1 | Completed | Akebia Therapeutics | 62 | 2018-07-20 | 2019-03-22 |
Showing 20 of 43. Sign in to see all of them.
Anemia (21) · Renal Insufficiency, Chronic (20) · Renal Insufficiency (12) · Kidney Diseases (4) · Kidney Failure, Chronic (3) · Anemia, Iron-Deficiency (2) · Hyperphosphatemia (2) · COVID-19 (1) · Complement Component 3 Deficiency, Autosomal Recessive (1) · Coronavirus Infections (1) · Disease Progression (1) · Glomerulonephritis, IGA (1) · Glomerulosclerosis, Focal Segmental (1) · Heart Failure (1) · Lupus Nephritis (1)
vadadustat (35) · Darbepoetin alfa (8) · Epoetin Alfa (4) · ferric citrate (3) · praliciguat (3) · Hematinics (2) · continuous erythropoietin receptor activator (2) · Atorvastatin (1) · Celecoxib (1) · Cyclosporins (1) · Digoxin (1) · Furosemide (1) · Moxifloxacin (1) · Pravastatin (1) · Probenecid (1)
United States (33) · Canada (8) · Brazil (5) · Italy (5) · Poland (5) · Argentina (4) · Mexico (4) · Russia (4) · South Korea (4) · Ukraine (4) · Australia (3) · Bulgaria (3) · France (3) · Germany (3) · Hungary (3)
Bentley J. Bobrow, MD (1) · Geoff Block, MD (1) · Jelena Seferovic, MD PhD (1) · John Hanrahan, MD MPH (1) · Paul Potnuru, MD (1)
PMID 36005278, PMID 40359056, PMID 33913637, PMID 33913638, PMID 37096396, PMID 39231617, PMID 27650732, PMID 28343225, PMID 32105984, PMID 33079154, PMID 33328269, PMID 37427292, PMID 38972306, PMID 39521398, PMID 40576086, PMID 40790188
2015 (2), 2016 (2), 2019 (1)